Funded by a nearly £1.2M (~$1.5M USD) award, this research will enable ongoing validation of AccelADx™, a breakthrough screening test for…
Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data…
NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-CalMALVERN, Pa., July 11, 2024 (GLOBE NEWSWIRE)…
Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potentialFS001…
Pragmatic registry provides high-quality real-world data on Alzheimer's disease, dementia, and mild cognitive impairment for research PALO ALTO, Calif. , July 10,…
The Fresh Start Award Program will grant up to five individuals a one-time prize of $10,000 to help them reach…
Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental healthMALVERN, Pa., July 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc.…
NEW YORK, July 9, 2024 /PRNewswire/ -- Scanning electrochemical microscopy (SECM) is used for imaging and analyzing chemical processes at…
Findings from preclinical study demonstrate potential for a field and prehospital treatment following a penetrating TBI NEW YORK, July 9,…
MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…
